Apr 4 |
ADC Therapeutics gains after data for lymphoma therapy
|
Apr 4 |
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|
Apr 3 |
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
|
Apr 1 |
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
|
Mar 19 |
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
|
Mar 16 |
US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results
|
Mar 15 |
ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
|
Mar 14 |
Q4 2023 ADC Therapeutics SA Earnings Call
|
Mar 13 |
ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript
|
Mar 13 |
ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation
|